pirenzepine

Summary

Summary: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Top Publications

  1. ncbi Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia
    R Michael Siatkowski
    Dean McGee Eye Institute University of Oklahoma Department of Ophthalmology, Oklahoma City, Oklahoma USA
    J AAPOS 12:332-9. 2008
  2. ncbi Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting
    Elisabeth Skogh
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 24:518-26. 2002
  3. ncbi Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid
    Martin Josefsson
    Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, SE 58133 Linköping, Sweden
    J Pharm Biomed Anal 53:576-82. 2010
  4. ncbi Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication
    Frank M Theisen
    Department of Child and Adolescent Psychiatry, University of Marburg, Marburg, Germany
    Ther Drug Monit 28:750-9. 2006
  5. ncbi A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine
    C Chin
    PPD Development, 2240 Dabney Road, Richmond, VA 23230, USA
    J Pharm Biomed Anal 35:1149-67. 2004
  6. ncbi Effects of pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans
    Yuhki Sato
    Department of Clinical Pharmacy, Oita University Hospital, Oita, Japan
    Biol Pharm Bull 29:166-71. 2006
  7. ncbi Pharmacokinetics and tissue distribution of olanzapine in rats
    M Aravagiri
    Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    Biopharm Drug Dispos 20:369-77. 1999
  8. pmc Myopia: attempts to arrest progression
    S M Saw
    Department of Community, Occupational and Family Medicine, National University of Singapore, 16 Medical Drive, Singapore 117597, Republic of Singapore
    Br J Ophthalmol 86:1306-11. 2002
  9. ncbi M1 muscarinic receptor modulation of Kir2 channels enhances temporal summation of excitatory synaptic potentials in prefrontal cortex pyramidal neurons
    David B Carr
    Dept of Neuroscience, Medical University of South Carolina, Charleston, USA
    J Neurophysiol 97:3432-8. 2007
  10. ncbi Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test
    J Aura
    Department of Neuroscience and Neurology, University of Kuopio, Finland
    Eur J Pharmacol 333:129-34. 1997

Research Grants

  1. CHOLINERGIC PHARMACOLOGY OF BASAL FOREBRAIN NEURONS
    Susan Robinson; Fiscal Year: 1990
  2. EFFECT OF PERINATAL ASPHYXIA ON STRIATUM
    Robert Burke; Fiscal Year: 1993
  3. SUBTYPE OF SELECTIVITY & MUSCARINIC RECEPTOR REGULATION
    William Messer; Fiscal Year: 1990
  4. Effects of antipsychotic drugs on brain and behavior
    FRANK TARAZI; Fiscal Year: 2005
  5. Norepinephrine Transporters: Targets for ADHD
    FRANK TARAZI; Fiscal Year: 2004
  6. Hybrid Drugs: Novel Pharmacotherapy for ADHD
    FRANK TARAZI; Fiscal Year: 2008
  7. Novel pharmacotherapies for treatment of ADHD
    FRANK TARAZI; Fiscal Year: 2003
  8. COMT genotype and response to cognitive remediation in schizophrenia
    Jean Pierre Lindenmayer; Fiscal Year: 2008
  9. Course and Morbidity in Bipolar I Disorder
    Ross Baldessarini; Fiscal Year: 2006
  10. Antidepressant discontinuation effects
    Ross Baldessarini; Fiscal Year: 2007

Detail Information

Publications230 found, 100 shown here

  1. ncbi Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia
    R Michael Siatkowski
    Dean McGee Eye Institute University of Oklahoma Department of Ophthalmology, Oklahoma City, Oklahoma USA
    J AAPOS 12:332-9. 2008
    To evaluate if the safety and efficacy of the relatively selective M1-antagonist, pirenzepine, in slowing the progression of myopia in children is sustained over a 2-year period.
  2. ncbi Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting
    Elisabeth Skogh
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 24:518-26. 2002
    ..The present TDM-based follow-up suggests that the influence of gender, smoking habits, and certain drug interactions may need to be considered for optimal dosage of OLA. TDM may be used for this purpose more readily in the future...
  3. ncbi Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid
    Martin Josefsson
    Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, SE 58133 Linköping, Sweden
    J Pharm Biomed Anal 53:576-82. 2010
    ..The method was successfully used for the analysis of samples from patients treated with olanzapine in the dose range of 2.5-25mg/day...
  4. ncbi Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication
    Frank M Theisen
    Department of Child and Adolescent Psychiatry, University of Marburg, Marburg, Germany
    Ther Drug Monit 28:750-9. 2006
    ..The data are compared with the literature, and the relevance of therapeutic antipsychotic drug monitoring in previously sparsely investigated subgroups, such as children and adolescents or patients with AN, is emphasized...
  5. ncbi A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine
    C Chin
    PPD Development, 2240 Dabney Road, Richmond, VA 23230, USA
    J Pharm Biomed Anal 35:1149-67. 2004
    ..Differential behavior between the analytes and labeled internal standards contributed to variability. The most significant source of variability however, was ion suppression due to co-eluting matrix components...
  6. ncbi Effects of pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans
    Yuhki Sato
    Department of Clinical Pharmacy, Oita University Hospital, Oita, Japan
    Biol Pharm Bull 29:166-71. 2006
    ..We examined the effects of the selective M(1) muscarinic receptor antagonist pirenzepine on the elevation of Dai-kenchu-to-induced plasma neuropeptide (gastrin, motilin, somatostatin, VIP, CGRP, ..
  7. ncbi Pharmacokinetics and tissue distribution of olanzapine in rats
    M Aravagiri
    Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    Biopharm Drug Dispos 20:369-77. 1999
    ..p. administration. The plasma concentration appears to predict the simultaneous concentration in brain and other tissues. There was no marked localized accumulation of olanzapine in any of the regions of the rat brain...
  8. pmc Myopia: attempts to arrest progression
    S M Saw
    Department of Community, Occupational and Family Medicine, National University of Singapore, 16 Medical Drive, Singapore 117597, Republic of Singapore
    Br J Ophthalmol 86:1306-11. 2002
    ....
  9. ncbi M1 muscarinic receptor modulation of Kir2 channels enhances temporal summation of excitatory synaptic potentials in prefrontal cortex pyramidal neurons
    David B Carr
    Dept of Neuroscience, Medical University of South Carolina, Charleston, USA
    J Neurophysiol 97:3432-8. 2007
    ..As a consequence of this dual modulation, the responses to a single, isolated afferent volley was reduced, but the response to a high-frequency afferent burst was potentiated...
  10. ncbi Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test
    J Aura
    Department of Neuroscience and Neurology, University of Kuopio, Finland
    Eur J Pharmacol 333:129-34. 1997
    ..the non-selective antagonist scopolamine (3 and 10 micrograms), the muscarinic M1 receptor-selective antagonist pirenzepine (10 and 30 micrograms) and the muscarinic M2 receptor-selective antagonist methoctramine (2, 5 and 20 ..
  11. ncbi Pirenzepine affects scleral metabolic changes in myopia through a non-toxic mechanism
    Hue Trung Truong
    Department of Optometry and Vision Sciences, The University of Melbourne, Victoria, 3010, Australia
    Exp Eye Res 74:103-11. 2002
    ..has been shown that various pharmacological agents, including the muscarinic receptor antagonists, atropine and pirenzepine, are effective at preventing the development of myopia...
  12. ncbi Olanzapine. Pharmacokinetic and pharmacodynamic profile
    J T Callaghan
    Lilly Laboratory for Clinical Research, Indiana University Hospital, Indianapolis, USA
    Clin Pharmacokinet 37:177-93. 1999
    ..However, dosage modification should be considered for patients characterised by a combination of factors associated with decreased oxidative metabolism, for example, debilitated or elderly women who are nonsmokers...
  13. ncbi Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor
    Chouaib Tahtaoui
    Laboratoire de Pharmacochimie de la Communication Cellulaire, Faculte de Pharmacie, UMR CNRS ULP 7081, IFR 85, 74 route du Rhin, BP 10413, 67412 Illkirch, France
    J Med Chem 47:4300-15. 2004
    ..between enhanced green fluorescent protein (EGFP)-fused human muscarinic M1 receptors and Bodipy-labeled pirenzepine, we synthesized seven fluorescent derivatives of this antagonist in order to further characterize ligand-..
  14. ncbi Deficits in avoidance responding after paradoxical sleep deprivation are not associated with altered [3H]pirenzepine binding to M1 muscarinic receptors in rat brain
    Karin M Moreira
    Psychobiology Department, Universidade Federal de Sao Paulo UNIFESP, Rua Napoleao de Barros 925, Sao Paulo 04024 002, SP, Brazil
    Brain Res 977:31-7. 2003
    ..are observed in non-deprived rats after treatment with M1-selective antagonist compounds such as dicyclomine or pirenzepine cause similar impairments, and gave rise to the hypothesis that sleep deprivation might induce significant ..
  15. pmc Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process
    Brigitte Ilien
    Département Biotechnologies des Interactions Moléculaires, Institut de Recherche de l Ecole de Biotechnologie de Strasbourg, FRE 3211, France
    J Biol Chem 284:19533-43. 2009
    ..We report here, using a combination of fluorescence approaches, on the molecular mechanisms for Bodipy-pirenzepine binding to enhanced green fluorescent protein (EGFP)-fused muscarinic M1 receptors in living cells...
  16. pmc Treatment options for myopia
    Jane Gwiazda
    Department of Vision Science, The New England College of Optometry, Boston, Massachusetts 02115, USA
    Optom Vis Sci 86:624-8. 2009
    ..various types of spectacle lenses and contact lenses, as well as pharmaceutical agents such as atropine and pirenzepine. The bulk of evidence from well-conducted studies shows that overall, most therapies for myopia have small ..
  17. ncbi The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans
    J W Lammers
    Department of Thoracic Medicine, Brompton Hospital, London, United Kingdom
    Am Rev Respir Dis 139:446-9. 1989
    In a double-blind randomized study, we compared the effects of the M1-selective muscarinic receptor antagonists pirenzepine and the nonselective antagonist ipratropium bromide on bronchoconstriction induced by inhaled sulfur dioxide (SO2)..
  18. ncbi Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study
    R Michael Siatkowski
    Department of Ophthalmology, University of Oklahoma, and Dean A McGee Eye Institute, Oklahoma City 73104, USA
    Arch Ophthalmol 122:1667-74. 2004
    To evaluate the safety and efficacy of the relatively selective M(1) antagonist pirenzepine hydrochloride in slowing the progression of myopia in school-aged children.
  19. ncbi Inhibition of myopia development in chicks using himbacine: a role for M(4) receptors?
    C L Cottriall
    Department of Optometry and Vision Sciences, University of Melbourne, Victoria 3010, Australia
    Neuroreport 12:2453-6. 2001
    The success of the M(1)-selective muscarinic antagonist pirenzepine in preventing myopia development in animal models implicates a role for the M(1) receptor...
  20. ncbi One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia
    Donald T H Tan
    Singapore Eye Research Institute and Singapore National Eye Centre, Singapore
    Ophthalmology 112:84-91. 2005
    To evaluate the safety and efficacy of the relatively selective M(1)-antagonist, pirenzepine ophthalmic gel (gel), in slowing the progression of myopia in school-aged children.
  21. ncbi Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain
    Margaret Piggott
    Newcastle General Hospital, MRC University of Newcastle Centre Development in Clinical Brain Ageing, MRC Building, Westgate Road, NE4 6BE, Newcastle upon Tyne, UK
    J Chem Neuroanat 24:211-23. 2002
    ..We have compared the in vitro binding of the muscarinic ligands [3H]pirenzepine and [3H]AF-DX 384, which have selectivity for the M1 and M2/M4 receptor subtypes, respectively, to the binding ..
  22. ncbi Embryonic chick heart expresses multiple muscarinic acetylcholine receptor subtypes. Isolation and characterization of a gene encoding a novel m2 muscarinic acetylcholine receptor with high affinity for pirenzepine
    K M Tietje
    Department of Pharmacology, University of Washington, Seattle 98195
    J Biol Chem 266:17382-7. 1991
    ..for the muscarinic antagonist quinuclidinyl benzilate and atropine, as well as the M1-selective antagonist pirenzepine and the M2-selective antagonist AF-DX 116...
  23. ncbi [Effects of pirenzepine on lens-induced myopia in the guinea-pig]
    Chao hu Ouyang
    Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai 200031
    Zhonghua Yan Ke Za Zhi 39:348-51. 2003
    To determine the efficacy of the M(1)-selective muscarinic antagonist, pirenzepine, in preventing lens-induced myopia in the guinea-pig and to study the mechanism and the possibility of treatment of myopia with pirenzepine.
  24. ncbi Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods
    M M Simpson
    Institute of Human Nutrition, Columbia University, USA
    J Clin Psychiatry 62:694-700. 2001
    ..Among the atypical drugs, olanzapine was associated with more weight gain than either clozapine or risperidone. The patient's admission BMI was not associated with the amount of weight gained during subsequent antipsychotic treatment...
  25. ncbi The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia
    D L Leslie
    VA Connecticut Mental Illness Research, Education and Clinical Center, West Haven, USA
    J Nerv Ment Dis 189:377-83. 2001
    ..Institutional fiscal pressure does not seem to reduce the broad availability of these medications overall but does affect which drug is prescribed...
  26. ncbi Role of ethnicity in predicting antipsychotic medication adherence
    Jayme L Opolka
    USMD Outcomes Research, Eli Lilly and Company, Indianapolis, IN, USA
    Ann Pharmacother 37:625-30. 2003
    ..Clinicians treating schizophrenia face increasingly diverse ethnic populations. Ethnic groups may have different approaches to the management of schizophrenia, which could impact antipsychotic medication adherence...
  27. ncbi Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States
    Peter D Feldman
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Med Dir Assoc 5:38-46. 2004
    ..The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications...
  28. ncbi A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia
    Cynthia S Palmer
    Center for Organization and Delivery Studies, Agency for Health Care Policy and Research, Rockville, MD, USA
    Arch Med Res 33:572-80. 2002
    ....
  29. ncbi Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
    S Kapur
    Schizophrenia Program, University of Toronto, Toronto, Canada
    Biol Psychiatry 50:873-83. 2001
    ....
  30. ncbi Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia
    D Gothelf
    Feinberg Child Study Center, Schneider Children s Medical Center of Israel
    J Neural Transm 110:545-60. 2003
    ..To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol...
  31. ncbi Similarities and differences among antipsychotics
    Carol A Tamminga
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9070, USA
    J Clin Psychiatry 64:7-10. 2003
    ..The treating physician must carefully match the diverse needs of schizophrenic patients with the varied characteristics of the second-generation antipsychotics...
  32. ncbi Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication
    S Moritz
    University of British Columbia, Department of Psychology, Vancouver, Canada
    Int Clin Psychopharmacol 17:41-4. 2002
    ..The difference between patients medicated with higher doses of conventional neuroleptics and those with lower doses was highly significant (P<0.001). In contrast, higher atypical neuroleptic doses were not associated with impairment...
  33. ncbi Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial
    Robert Rosenheck
    Department of Veterans Affairs Medical Center, West Haven, Conn, USA
    JAMA 290:2693-702. 2003
    ..Although olanzapine has been widely adopted as a treatment of choice for schizophrenia, its long-term effectiveness and costs have not been evaluated in a controlled trial in comparison with a standard antipsychotic drug...
  34. ncbi Service use and costs of treating schizophrenia with atypical antipsychotics
    M Lewis
    Section of Neurobiology of Psychosis, Institute of Psychiatry, De Crespigny Park, London, England
    J Clin Psychiatry 62:749-56. 2001
    ..CONCLUSION: Clozapine was reserved for more severe forms of schizophrenia, but its cost impact was relatively low. Risperidone, as prescribed in ordinary practice, may be more cost-effective than olanzapine...
  35. ncbi Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics
    Eugenio Aguglia
    Department of Clinical, Morphological and Technological Sciences, U C O of Clinical Psychiatry, University of Trieste, Via Paolo de Ralli n 5, 34147 Trieste, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 26:1229-33. 2002
    ..The level of insight was increased after the administration of the atypical antipsychotics. The cognitive effect of the atypical antipsychotics changed the level of insight and augmented the compliance...
  36. ncbi Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  37. ncbi Safety in treating bipolar disorder
    Sanjay Gupta
    School of Medicine and Biomedical Sciences, State University of New York at Buffalo, USA
    J Fam Pract . 2003
  38. ncbi alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs
    Hans O Kalkman
    Novartis Pharma AG, Research Nervous System, Building WSJ 360 405, CH 4002 Basel, Switzerland
    Eur J Pharmacol 462:33-40. 2003
    ..Clozapine had the highest alpha(2C)/D(2) selectivity, and iloperidone the highest alpha(2C)/alpha(2A) ratio. It is hypothesised that alpha(2C)-adrenoceptor blockade contributes to improvement of cognitive function...
  39. ncbi Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Psychoneuroendocrinology 28:69-82. 2003
    ..A discrimination of prolactin-sparing versus prolactin-elevating antipsychotic drugs may provide the clinician with treatment choices in order to avoid or mitigate hyperprolactinemia-associated morbidity...
  40. ncbi [Viewpoint of schizophrenic patients: a European survey]
    P Courtet
    , , CHU Montpellier 34295
    Encephale 27:28-38. 2001
    ....
  41. ncbi Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
    J Czekalla
    Medical CNS Division, Lilly Deutschland, Bad Homburg, Germany
    J Clin Psychiatry 62:191-8. 2001
    ....
  42. ncbi [Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia]
    J Rabe-Jabłońska
    II Kliniki Psychiatrycznej Katedry Psychiatrii AM w Łodzi
    Psychiatr Pol 35:47-57. 2001
    ....
  43. ncbi A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
    R R Conley
    Maryland Psychiatric Research Center, University of Maryland, USA
    Am J Psychiatry 158:765-74. 2001
    ..There was no measure on which olanzapine was superior. Greater weight gain was associated with olanzapine than with risperidone treatment...
  44. ncbi Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia
    Blanka Kores Plesnicar
    Department of Psychiatry, Teaching Hospital Maribor, Maribor, Slovenia
    Wien Klin Wochenschr 115:58-62. 2003
    ..The aim of the present study was to establish whether any changes occur in simple reaction time during treatment with risperidone or olanzapine in in-patients suffering a relapse of schizophrenia...
  45. ncbi [Treatment of schizophrenia in subjects with substance use disorders: A review]
    G Rubio Valladolid

    Actas Esp Psiquiatr 29:124-30. 2001
    ..CONCLUSIONS: In spite of underlyng methodological problems of these studies, the findings suggest that atypical antipsychatics could be the treatment of choice in these patients...
  46. ncbi Comparative effectiveness of antipsychotic drugs
    Andrea Messori
    Am J Psychiatry 160:591-2; author reply 592-3. 2003
  47. ncbi Schizophrenia, VI: Treatments
    Jeffrey A Lieberman
    UT Southwestern Medical Center, Department of Psychiatry, Dallas TX 75390 9070, USA
    Am J Psychiatry 160:1748. 2003
  48. ncbi Comparative effectiveness of antipsychotic drugs
    Richard C Meibach
    Am J Psychiatry 160:589-90; author reply 592-3. 2003
  49. ncbi Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone
    B R Basson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 62:231-8. 2001
    ..Choice of atypical antipsychotic drug (olanzapine vs. risperidone) was of minor importance with regard to influence on acute weight gain...
  50. ncbi Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    Am J Psychiatry 159:255-62. 2002
    ....
  51. ncbi Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
    Uriel Heresco-Levy
    Ezrath Nashim Herzog Memorial Hospital, Jerusalem, Israel
    Am J Psychiatry 159:480-2. 2002
    ..The authors investigated the clinical effects of D-cycloserine when added to treatment with conventional neuroleptics, olanzapine, or risperidone for treatment-resistant schizophrenia...
  52. ncbi Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region
    Ellen M Weissman
    Bronx VA Medical Center, NY 10468, USA
    Schizophr Bull 28:31-42. 2002
    ..Additional research in everyday practice settings is needed to address clinical questions unlikely to be answered through traditional efficacy research and to examine reasons for intersite differences in prescribing patterns...
  53. ncbi [Neuroleptics and cognition]
    Alexander Brunnauer
    Bezirksklinikum Gabersee, Abteilung Neuropsychologie, 83512 Wasserburg Inn
    Psychiatr Prax 30:S106-9. 2003
    ..The aim of this study was to evaluate the effects of atypical antipsychotics on cognitive function in schizophrenic patients under clinical routine conditions...
  54. ncbi Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine
    M Markianos
    Athens University Medical School, Psychiatric Clinic, Eginition Hospital, Vas Sophias 74, 11528 Athens, Greece
    Schizophr Res 56:11-7. 2002
    ....
  55. ncbi Extreme weight gain in a youth with schizophrenia: risk/benefit considerations
    Duncan Webster
    Schizophr Res 56:187-9. 2002
  56. ncbi The effects of novel antipsychotics on glucose and lipid levels
    Donna A Wirshing
    Department of Psychiatry, VA Greater Los Angeles Healthcare System, and University of California at Los Angeles, School of Medicine, 90073, USA
    J Clin Psychiatry 63:856-65. 2002
    ..The goal of this study is to compare the effects of novel antipsychotics clozapine, olanzapine, risperidone, and quetiapine and typical antipsychotics haloperidol and fluphenazine on glucose and lipid levels...
  57. ncbi Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder
    Carla M Canuso
    Commonwealth Research Center, Boston, MA 02115, USA
    Psychiatry Res 111:11-20. 2002
    ....
  58. ncbi Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study
    J Bobes
    Department of Psychiatry, University of Oviedo, Spain
    J Sex Marital Ther 29:125-47. 2003
    ..Quetiapine appears to improve this profile during short-term treatment; however, longterm data, with larger samples, are required with this latter drug...
  59. ncbi Rehospitalization risk with second-generation and depot antipsychotics
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:23-31. 2003
    ..SGAs may provide better long-term prognoses and outcomes for patients with schizophrenia...
  60. ncbi The value of atypical antipsychotics in the treatment of schizophrenia
    Lois M Jessen
    Rutgers University, Ernest Mario School of Pharmacy, Robert Wood Johnson University Hospital, USA
    Manag Care 11:8-12; discussion 12-3. 2002
  61. ncbi Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial
    Wai Kwong Tang
    Department of Psychiatry, Chinese University Hong Kong, Prince Wales Hospital, Hong Kong SAR, China
    J ECT 18:90-4. 2002
    ..In addition, they were significantly better in terms of BPRS and SANS scores, as well as work performance and social functioning at the 2-month post-ECT evaluation...
  62. ncbi Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol
    Scot E Purdon
    Department of Psychiatry, University of Alberta, CHA ANE, Box 307, Edmonton, Alberta, Canada T5J 2J7
    Psychopharmacology (Berl) 169:390-7. 2003
    ..Olanzapine is pharmacologically similar to clozapine and has a low incidence of EPS induction...
  63. ncbi Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia
    Mustafa Bilici
    BlackSea Technical University, School of Medicine, Department of Psychiatry, 61080, Trabzon, Turkey
    Int J Neurosci 112:817-28. 2002
    ..These findings suggest that atypical neuroleptics may be safer than the classical neuroleptics in terms of reduced BMD...
  64. ncbi Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients
    Hassan S Dinakar
    Rockland Psychiatric Center, Orangeburg, New York 10962, USA
    Psychiatr Serv 53:755-7. 2002
    ..There is value in reassessing long-stay patients who have treatment-refractory schizophrenia and giving them systematic trials with new medications that become available...
  65. ncbi Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  66. ncbi Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders
    Lieuwe De Haan
    Adolescent Clinic, Academic Medical Center, University ofAmsterdam, Department of Psychiatry, The Netherlands
    J Clin Psychiatry 63:104-7. 2002
    ..To determine whether severity of obsessive-compulsive symptoms (OCS) differs during treatment with olanzapine or risperidone and to establish whether duration of antipsychotic treatment is related to severity of OCS...
  67. ncbi Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine
    Deanna L Kelly
    J Clin Psychiatry 64:1133-4. 2003
  68. ncbi [Clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated with risperidone or olanzapine]
    B Hamel
    C.H. Haguenau, Service Pharmacie, , 67 504 Haguenau, France
    Therapie 56:645-52. 2001
    ....
  69. ncbi Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia
    Daniel E Casey
    Mental Illness Research, Education, and Clinical Center, Portland VA Medical Center, OR 97201, USA
    Neuropsychopharmacology 28:182-92. 2003
    ..Further evaluation is warranted to confirm these findings...
  70. ncbi [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients]
    P Briken
    Zentrum fur Psychosoziale Medizin, Psychiatrie und Psychotherapie, Universitatsklinikum Hamburg Eppendorf, Germany
    Fortschr Neurol Psychiatr 70:139-44. 2002
    ..In persistent aggression clozapin shows the best specific results. Typical depot neuroleptics should be considered in cases when medication compliance is a problem...
  71. ncbi Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders
    I D Glick
    Stanford University School of Medicine, Department of Psychiatry, CA 94305, USA
    Int Clin Psychopharmacol 17:65-8. 2002
    ....
  72. ncbi Racial disparity in the use of atypical antipsychotic medications among veterans
    Laurel A Copeland
    VA Health Services Research and Development Field Office, Ann Arbor, Mich, 48113 0170, USA
    Am J Psychiatry 160:1817-22. 2003
    ..This study assessed the current state of antipsychotic prescription practices regarding race among veterans receiving care through the Department of Veterans Affairs...
  73. ncbi Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics
    Murad Atmaca
    Department of Psychiatry, School of Medicine, Firat University, Elazig, Turkey
    J Clin Psychiatry 64:598-604. 2003
    ..We planned to comparatively investigate the effects of the atypical antipsychotics quetiapine, olanzapine, risperidone, and clozapine on leptin and triglyceride levels and weight gain...
  74. ncbi Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia
    Michael J Sernyak
    Psychiatry Service, VA Connecticut Healthcare System, West Haven, 06516, USA
    Am J Psychiatry 159:561-6. 2002
    ..This study used administrative data from a large national sample of patients with a diagnosis of schizophrenia to compare the prevalence of diabetes mellitus in patients receiving prescriptions for atypical and typical neuroleptics...
  75. ncbi Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents
    James P Kelleher
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    CNS Drugs 16:249-61. 2002
    ..These new formulations and agents should broaden options for the treatment of psychosis...
  76. ncbi Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia
    X S Ren
    Health Outcomes Technologies, Health Services Department, Boston University School of Public Health, Boston, MA, USA
    J Clin Pharm Ther 27:441-51. 2002
    ..The treatment of schizophrenia is therefore particularly important to reduce deficits across a large number of neurocognitive domains...
  77. ncbi Chlorpromazine equivalent doses for the newer atypical antipsychotics
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    J Clin Psychiatry 64:663-7. 2003
    ..Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed...
  78. ncbi Elevation of prolactin levels by atypical antipsychotics
    Peter Turrone
    Department of Psychiatry, University of Toronto, Ont, Canada
    Am J Psychiatry 159:133-5. 2002
    ..Atypical antipsychotics are thought not to elevate prolactin levels. The authors examined data suggesting that atypical antipsychotics do elevate prolactin levels but more transiently than typical antipsychotics...
  79. ncbi Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study
    J Bobes
    Department of Psychiatry, University of Oviedo, c Julian Claveria, 6, 33006, Oviedo, Spain
    Schizophr Res 62:77-88. 2003
    ..The aim of this cross-sectional study, the EIRE study, was to assess the frequency of several side effects with antipsychotics in the clinical setting. This paper addresses the adverse effect of weight gain...
  80. pmc Mediation by the same muscarinic receptor subtype of phasic and tonic contractile activities in the rat isolated portal vein
    M Pfaffendorf
    Department of Pharmacotherapy, University of Amsterdam, The Netherlands
    Br J Pharmacol 108:132-8. 1993
    ..AF-DX116, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP), P-fluorohexahydrosiladiphenidol (pFHHSiD) and pirenzepine antagonized the phasic and tonic mechanical responses to carbachol...
  81. pmc Characterization of the interaction between muscarinic M2 receptors and beta-adrenoceptor subtypes in guinea-pig isolated ileum
    H Reddy
    Syntex Discovery Research, Institute of Pharmacology, Palo Alto, CA 94303
    Br J Pharmacol 114:49-56. 1995
    ..0 +/- 0.2)>methoctramine (7.1 +/- 0.1) >p-fluoro-hexa-hydrosilaphenidol (p-F-HHSiD; 6.5 +/- 0.2) ) pirenzepine(6.3 +/- 0.2). (+)-cis-dioxolane also significantly inhibited BRL 37344 (10 IM; 56.5 +/-2...
  82. pmc Secretory and radioligand binding studies on muscarinic receptors in bovine and feline chromaffin cells
    J J Ballesta
    Departmento de Neuroquimica, Universidad de Alicante, Facultad de Medicina, Spain
    J Physiol 418:411-26. 1989
    ..Preferential displacement by atropine over pirenzepine suggests that the binding site is associated to a M2-type muscarinoceptor. 5...
  83. ncbi Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors
    M S Reid
    Stanford University, Sleep Disorders Research Center, Palo Alto, California 94304
    Sleep 17:424-35. 1994
    ..and gallamine (M2 muscarinic), partially reversed by 4-DAMP (M3/M1 muscarinic) and completely unaffected by pirenzepine (M1 muscarinic)...
  84. ncbi Variable effects of previously untested muscarinic receptor antagonists on experimental myopia
    W Alana Luft
    Department of Cell Biology and Anatomy, Lions Sight Center and Neuroscience Research Group, University of Calgary, Calgary, Alberta, Canada
    Invest Ophthalmol Vis Sci 44:1330-8. 2003
    Atropine, pirenzepine, and himbacine prevent form-deprivation myopia (FDM) when administered intravitreously. The mechanisms and sites of action of these drugs against myopia are not clear...
  85. pmc Heterogeneity of muscarinic receptors in lamb isolated coronary resistance arteries
    U Simonsen
    , Facultad de Veterinaria, Universidad Complutense, Madrid, Spain
    Br J Pharmacol 109:998-1007. 1993
    ..Preferential muscarinic receptor antagonists were used to determine the receptor subtype: pirenzepine (M1 receptor), AFDX 116 (M2 receptor), 4-DAMP and pFHHSiD (M3 receptor). 2...
  86. ncbi Characterization of muscarinic receptors mediating vasodilation in guinea-pig ileum submucosal arterioles by the use of computer-assisted videomicroscopy
    E Bungardt
    Department of Pharmacology, University of Frankfurt, Germany
    Eur J Pharmacol 213:53-61. 1992
    ..The muscarinic antagonists pirenzepine, (+-)-5,11-dihydro-11-[[[2-[2-((dipropylamino)methyl)-1-piperidinyl] ethyl]amino]-carbonyl]-6H-pyrido(2,3-b)(1,..
  87. ncbi Postsynaptic integration of cholinergic and dopaminergic signals on medium-sized GABAergic projection neurons in the neostriatum
    L G Harsing
    Department of Neuroscience, University of Pittsburgh, PA, USA h 13768
    Brain Res Bull 45:607-13. 1998
    ..by the nonselective muscarinic antagonist atropine (1 microM) and the selective M1 receptor antagonist pirenzepine (0.1-1.0 microM). The M2 receptor antagonist methoctramine (1...
  88. ncbi Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases
    C L Silveira
    Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore 21201
    Toxicol Appl Pharmacol 103:474-81. 1990
    ..protein) was detected and [3H]CD binding was sensitive to the M2 antagonist himbacine but much less so to pirenzepine, the M1 antagonist...
  89. pmc Characterization of muscarinic receptors that mediate contraction of guinea-pig isolated trachea to choline esters: effect of removing epithelium
    K J Morrison
    Center for Experimental Therapeutics, Baylor College of Medicine, Houston, TX 77030
    Br J Pharmacol 106:672-6. 1992
    ..acetic and carbamic acid choline esters was determined by use of preferential muscarinic receptor antagonists: pirenzepine (M1 receptor), methoctramine (M2 receptor) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) (M3 receptor). 2...
  90. ncbi Experimental localization of muscarinic receptor subtypes to cingulate cortical afferents and neurons
    B A Vogt
    Department of Anatomy, Boston University School of Medicine, Massachusetts 02118
    J Neurosci 8:643-52. 1988
    ..The index was calculated by first determining the laminar distribution of pirenzepine (PZ) binding sites and then summing absolute laminar variations from this distribution for each ligand...
  91. pmc Effects of muscarinic M2 and M3 receptor stimulation and antagonism on responses to isoprenaline of guinea-pig trachea in vitro
    N Watson
    Syntex Discovery Research, Institute of Pharmacology R2 101, Palo Alto, CA 94303
    Br J Pharmacol 112:179-87. 1994
    ..1) > zamifenacin (8.2 +/- 0.1) > para-fluoro-hexahydro-siladiphenidol (p-F-HHSiD, 7.2 +/- 0.1) > pirenzepine (6.5 +/- 0.1) > methoctramine (5.5 +/- 0.1). Schild slopes were not significantly different from unity...
  92. ncbi Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment
    W M Hui
    Department of Medicine, University of Hong Kong, Queen Mary Hospital
    Am J Med 92:265-74. 1992
    ..We performed a randomized controlled trial to compare the efficacy of seven forms of maintenance treatment of duodenal ulcer, including a mealtime regimen of antacids...
  93. ncbi Muscarinic M1 acetylcholine receptors regulate the non-quantal release of acetylcholine in the rat neuromuscular junction via NO-dependent mechanism
    Artem I Malomouzh
    Kazan Institute of Biochemistry and Biophysics, Russian Academy of Sciences, Kazan, Russia
    J Neurochem 102:2110-7. 2007
    ..The muscarinic agonists oxotremorine and muscarine lowered the H-effect and the M1 antagonist pirenzepine prevented this effect occurring at all...
  94. pmc Contrasting effects of carbachol, McN-A-343 and AHR-602 on Ca(2+)-mobilization and Ca(2+)-influx pathways in taenia caeci
    S Hishinuma
    Department of Pharmacology, Meiji College of Pharmacy, Tokyo, Japan
    Br J Pharmacol 122:985-92. 1997
    ..of the muscarinic receptor subtype that had a high affinity for 4-DAMP (M3 selective) but a low affinity for pirenzepine (M1 selective) and AF-DX 116 (M2 selective)...
  95. pmc Functional characterization of muscarinic receptors in murine airways
    J Garssen
    Department of Pharmacology, Faculty of Pharmacy, University of Utrecht, The Netherlands
    Br J Pharmacol 109:53-60. 1993
    1. The effects of muscarinic receptor antagonists considered to be selective for M1 receptors (pirenzepine; PZ), M2 receptors (AFDX-116), and for M3 receptors (4-diphenyl acetoxy N-methyl-piperidine (4-DAMP)) were used to investigate the ..
  96. pmc Effects of cholinesterase inhibition in supraspinal and spinal neural pathways on the micturition reflex in rats
    Hitoshi Masuda
    Department of Urology, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
    BJU Int 104:1163-9. 2009
    ..To investigate whether activation of brain and spinal cholinergic pathways affects the micturition reflex in rats...
  97. pmc No evidence for a role of muscarinic M2 receptors in functional antagonism in bovine trachea
    A F Roffel
    Groningen Utrecht Institute for Drug Exploration, Department of Medicinal Chemistry and Molecular Pharmacology, University of Groningen, The Netherlands
    Br J Pharmacol 115:665-71. 1995
    ..biochemical responses to this functional antagonism was investigated with the selective muscarinic antagonists, pirenzepine (M1 over M2), AF-DX 116 and gallamine (M2 over M3), and hexahydrosiladiphenidol (M3 over M2). 2...
  98. ncbi Pharmacological evidence that nitric oxide mediates the antinociception produced by muscarinic agonists in the rostral ventral medulla of rats
    E T Iwamoto
    Department of Pharmacology, University of Kentucky College of Medicine, Lexington
    J Pharmacol Exp Ther 269:699-708. 1994
    ..4 and 1.7 nmol, respectively. Five-minute preinjections with 0.35 nmol of the muscarinic M1 receptor blocker pirenzepine competitively antagonized the antinociception produced by (+)-cis-methyldioxolane...
  99. ncbi Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes
    J Pavia
    Department of Pharmacology, Malaga School of Medicine, Malaga University, Spain
    Eur J Pharmacol 320:209-14. 1997
    ..of these receptors, competition binding experiments were carried out using the muscarinic receptor antagonists pirenzepine, (11(2-diethyl-amino)methyl)-1-piperidinylacetyl-5-11-dihydro-6H-py rido(14) benzodiazepine (AF-DX 116), ..
  100. ncbi Muscarinic excitation and inhibition of neurons in the submucous plexus of the guinea-pig caecum
    S Mihara
    Department of Physiology, Kurume University School of Medicine, Japan
    Neuroscience 31:247-57. 1989
    ..Low concentrations of pirenzepine reversibly antagonized both responses...
  101. pmc Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigs
    C H Lin
    Pharmacological Institute, College of Medicine, National Taiwan University, Taipei
    Br J Pharmacol 113:275-81. 1994
    ..92 +/- 0.05), but was less potent than atropine (pA2 = 8.93 +/- 0.07), pirenzepine (pA2 = 7.02 +/- 0.09) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, pA2 = 8.72 +/- 0.07). 3...

Research Grants67

  1. CHOLINERGIC PHARMACOLOGY OF BASAL FOREBRAIN NEURONS
    Susan Robinson; Fiscal Year: 1990
    ..depending upon the results of the agonist studies, the ability of some or all of the following antagonists to block the action of carbachol, will be studied: mecamylamine, atropine, pirenzepine, AF-DX 116 and hexahydrosila-difenidol.
  2. EFFECT OF PERINATAL ASPHYXIA ON STRIATUM
    Robert Burke; Fiscal Year: 1993
    ..will be made by parallel assay of total muscarinic binding (using 3H-QNB) and M1 binding (using 3H-pirenzepine)...
  3. SUBTYPE OF SELECTIVITY & MUSCARINIC RECEPTOR REGULATION
    William Messer; Fiscal Year: 1990
    ..This will be accomplished by measuring the effects of exposures to pirenzepine, gallamine and AFDX-116 on the number and affinity of muscarinic receptors through autoradiographic methods...
  4. Effects of antipsychotic drugs on brain and behavior
    FRANK TARAZI; Fiscal Year: 2005
    ..adult rats, and should evolve new principles for improved treatments for childhood-onset schizophrenia and other major pediatric psychiatric disorders. ..
  5. Norepinephrine Transporters: Targets for ADHD
    FRANK TARAZI; Fiscal Year: 2004
    ..Expected findings should lead to novel compounds that can be developed as much needed innovative non-stimulant treatments for ADHD and other major neuropsychiatric disorders. ..
  6. Hybrid Drugs: Novel Pharmacotherapy for ADHD
    FRANK TARAZI; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  7. Novel pharmacotherapies for treatment of ADHD
    FRANK TARAZI; Fiscal Year: 2003
    ..Expected findings should evolve new principles and lead to novel compounds that can be used as much-needed innovative treatments for ADHD and other major neuropsychiatric disorders. ..
  8. COMT genotype and response to cognitive remediation in schizophrenia
    Jean Pierre Lindenmayer; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  9. Course and Morbidity in Bipolar I Disorder
    Ross Baldessarini; Fiscal Year: 2006
    ..Anticipated findings should contribute important new information to guide effective interventions and allocation of increasingly limited treatment resources for BPD patients. ..
  10. Antidepressant discontinuation effects
    Ross Baldessarini; Fiscal Year: 2007
    ..bipolar depressive subjects separately. The findings expected should contribute to improved safety of antidepressant treatment and reduced morbid and mortal risks following its discontinuation. [unreadable] [unreadable]..
  11. Enhancing the Prospective Prediction of Psychosis
    Scott Woods; Fiscal Year: 2007
    ..Each site has provefi its ability to recruit prodromal patients in a previous collaboration. ..
  12. Northeast Under/Grad Research Organization for Neuroscience
    Cheryl Frye; Fiscal Year: 2008
    ..Both of these outcomes are congruous with the Public Health Service's mission to ensure that there is a resource of well-trained scientists and health-care providers in the United States. [unreadable] [unreadable] [unreadable]..
  13. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    Scott Woods; Fiscal Year: 2003
    ..Thus, we are proposing to add these aims. ..
  14. TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC
    Scott Woods; Fiscal Year: 2004
    ..The existence of a previous sample at the same site provides a useful additional comparison group. Methods including sample ascertainment and TD assessment are closely modeled after the original work. ..
  15. Metabolic Effects of Newer Antipsychotics in Older Pts
    Dilip Jeste; Fiscal Year: 2009
    ..abstract_text> ..
  16. Cue dependency with intravenous nutrients and nicotine
    Neil Rowland; Fiscal Year: 2007
    ..These studies may help to develop ways in conditioned preferences can be manipulated to prevent or treat certain addictive disorders, including overeating. [unreadable] [unreadable] [unreadable]..
  17. BIOPHYSICAL AND BIOCHEMICAL PHARMACOLOGY
    GEOFFREY SHARP; Fiscal Year: 2007
    ..abstract_text> ..
  18. Course of Functional Deficits in Late-Life Schizophrenia
    Philip Harvey; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  19. Apathy in Alzheimer's Disease Methylphenidate Trial
    Paul B Rosenberg; Fiscal Year: 2010
    ..This study aims to develop a new treatment for apathy in AD that could decrease its debilitating consequences and reduce patients'dependency on caregivers, providing well-deserved relief to patients and their loved ones. ..
  20. EMMETROPIZATION AND DEVELOPMENT OF MYOPIA IN CHILDREN
    Jane Gwiazda; Fiscal Year: 2005
    ....
  21. Gender and Brain Abnormalities in Schizophrenia
    Jill M Goldstein; Fiscal Year: 2010
    ....
  22. DVD Consent for Research in Older Schizophrenia Patients
    Dilip Jeste; Fiscal Year: 2008
    ..The DVD-based consent is not intended to supplant, but rather to supplement, the researcher-participant in-person interaction involved in consent process. ..
  23. A Novel Animal Model of Relevance to Schizophrenia
    David Feifel; Fiscal Year: 2009
    ..The successful development of this animal model could significantly enhance the understanding of the underlying causes of schizophrenia-associated abnormalities and improve drug discovery. ..
  24. Aging, Serotonin and Reversal Learning
    MICHAEL RAGOZZINO; Fiscal Year: 2008
    ..These studies have the potential of developing a novel treatment for the learning and memory deficits observed in aging and Alzheimer's disease. [unreadable] [unreadable] [unreadable]..
  25. Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay
    Murray Stein; Fiscal Year: 2008
    ..Enhancing the development of new treatments for anxiety is a public health priority. The projects proposed in this application have the potential to achieve this important aim. [unreadable] [unreadable] [unreadable]..
  26. Institute for Research Minority Training on Mental Health
    Jacobo Mintzer; Fiscal Year: 2007
    ..We expect this effort to be the incubator for a new generation of minority researchers dedicated to the study mental health and aging. ..
  27. Improving Outcomes in Pharmacotherapy of Social Phobia
    Murray Stein; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  28. MODEL OF HYPERCORTISOLISM FOR MAJOR DEPRESSION
    Alan F Schatzberg; Fiscal Year: 2010
    ....
  29. Signal Transduction in Depression
    Richard Shelton; Fiscal Year: 2008
    ..These studies may shed light on important cellular mediators of depression and provide new targets for amelioration. [unreadable] [unreadable]..
  30. Childhood Physiology and Risk for Schizophrenia
    Randal Ross; Fiscal Year: 2008
    ..Clarification of this methodology may lead to a novel prenatal intervention strategy designed to decrease risk for adolescent and adult onset of psychosis. ..
  31. Abnormal Eye Movement in Schizophrenia: Genome-Wide Scan
    Randal Ross; Fiscal Year: 2008
    ..Linkage in both groups will assessed using methods capable of detecting genetic effects on quantitative traits. ..
  32. Promoting Adherence to Treatment in Schizophrenia
    Alex Kopelowicz; Fiscal Year: 2006
    ..abstract_text> ..
  33. MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT
    Matthew Byerly; Fiscal Year: 2006
    ..abstract_text> ..
  34. GLUCOSE METABOLISM AND AUGMENTATION OF INSULIN RELEASE
    GEOFFREY SHARP; Fiscal Year: 2001
    ....
  35. Chinese Exercise Modalites in Parkinson's Disease
    Jorge Juncos; Fiscal Year: 2003
    ..A better understanding of exercise-induced neural plasticity and motor control would offer a significant, and heretofore unexploited rehabilitative potential in PD. ..
  36. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    Stephen Marder; Fiscal Year: 2003
    ..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
  37. MULTIPLE FAMILY GROUPS FOR LATINOS WITH SCHIZOPHRENIA
    Alex Kopelowicz; Fiscal Year: 2003
    ..Academic and research activities will take place throughout the award period. ..
  38. Ginkgo biloba for ECT-induced Memory Deficits
    JOHN MARKOWITZ; Fiscal Year: 2003
    ..will utilize larger groups and additional cognitive tests will be incorporated to provide more definitive conclusions regarding efficacy, optimal dose and duration, persistence of effects, and safety and tolerability ..
  39. IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE
    Murray Stein; Fiscal Year: 2002
    ..abstract_text> ..
  40. PARTIAL DOPAMINEAGONIST TREATMENT OF SCHIZOPHRENIA
    Carol Tamminga; Fiscal Year: 2002
    ..These data will predict and later help us to select optimal agonist intrinsic activity ior clinical testing for antipsychotic actvity, duration of therapeutic action, and side effects. ..
  41. PHARMACOTHERAPY OF ADOLESCENT BODY DYSMORPHIC DISORDER
    Eric Hollander; Fiscal Year: 2002
    ..When untreated, adolescent-onset BDD appears to often interfere with the developmental tasks of adolescence, to persist, and to cause substantial morbidity through out the life span. ..
  42. Screening Herbs for Drug Interactions
    JOHN MARKOWITZ; Fiscal Year: 2002
    ..Further, the proposed studies will complement existing and future NCCAM studies of agents such as St. John's wort and Gingko biloba. ..
  43. BRAIN CHOLINE UPTAKE AND LATE LIFE MENTAL ILLNESS
    Bruce Cohen; Fiscal Year: 2002
    ..In addition, the proposed experiments represent a unusual opportunity to study an age-related decline in function in adult humans which may be addressable by nutritional or pharmacologic means. ..
  44. LATE ONSET SCHIZOPHRENIA--A NEUROPSYCHIATRIC STUDY
    Dilip Jeste; Fiscal Year: 2002
    ..g., MRI quantitative analysis, outcome and functioning measures) to the new questions being asked. Our studies should have a major impact on the understanding of schizophrenia and aging. ..
  45. EARLY DETECTION AND INTERVENTION IN PSYCHOSIS
    Thomas McGlashan; Fiscal Year: 2003
    ..abstract_text> ..
  46. Divalproex Sodium/Placebo In Child/Adolesent Autism
    Eric Hollander; Fiscal Year: 2003
    ....
  47. MECHANISMS OF INHIBITION OF INSULIN RELEASE BY GALANIN
    GEOFFREY SHARP; Fiscal Year: 2006
    ..4) To determine which G-protein subunits are associated with the inhibitory effects. 5) To determine the targets of protein actylation in the distal action of the inhibitors. ..
  48. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2004
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  49. MECHANISMS OF CHLORPYRIFOS DEVELOPMENTAL NEUROTOXICITY
    Theodore Slotkin; Fiscal Year: 2004
    ..Molecular mechanisms of developmental neurotoxicity can be determined and linked to eventual alterations in behavioral performance. ..
  50. Antipsychotic-Like Drug Effects of Neurotensin
    David Feifel; Fiscal Year: 2004
    ....
  51. Perinatal Vulnerability to Psychosis
    Randal Ross; Fiscal Year: 2004
    ....
  52. TREATMENT OF EARLY ONSET SCHIZOPHRENIA SPECTRUM (TEOSS)
    Robert Findling; Fiscal Year: 2005
    ..This study will provide information about the comparative effectiveness of the most commonly used and representative antipsychotic drugs in youth with schizophrenia spectrum disorders. ..
  53. HPA AXIS/DOPAMINE INTERACTIONS IN PSYCHOTIC DEPRESSION
    Alan Schatzberg; Fiscal Year: 2009
    ..Of particular importance is that the treatment may be effective even when given intermittently. ..
  54. Cholinergic modulation of IEG expression
    ANN POWER; Fiscal Year: 2006
    ..Experiment III will investigate which signaling cascades (e.g., protein kinases) are involved in effects of mR activation on memory and immediate early gene expression. ..
  55. Examination of the Limbic Cortex in Schizophrenia
    Carol Tamminga; Fiscal Year: 2006
    ..These data will have implications for understanding the mechanisms of the illness and for directing future new drug discovery for schizophrenia therapeutics. ..
  56. Fetal & Adolescent Nicotine Effects on CNS 5HT Systems
    Theodore Slotkin; Fiscal Year: 2003
    ..abstract_text> ..
  57. Nicotinic-Purinergic Modulation of Bladder Contraction
    George Somogyi; Fiscal Year: 2009
    ..Finally, we will utilize readily available nicotinic receptor knockout mice to functionally confirm the modulatory role of specific nicotinic receptors on mouse bladder contractions. ..
  58. Striatal Acetylcholine and Behavioral Flexibility
    MICHAEL RAGOZZINO; Fiscal Year: 2005
    ....
  59. REVAMP-Follow-Up Study
    Alan Schatzberg; Fiscal Year: 2008
    ....
  60. Comparitive Antipsychotic Drug Actions on Brain Neurochemistry
    Carol Tamminga; Fiscal Year: 2007
    ..Concentration on mouse behaviors, neurochemistry and behavior will advance studies aimed at kinetic applications. ..
  61. COLLABORATIVE LONGITUDINAL STUDY OF PERSONALITY DISORDER
    Thomas McGlashan; Fiscal Year: 2008
    ....
  62. Antipsychotic Actions in Models of NMDA Hypofunction
    Gary Duncan; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  63. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  64. MOLECULAR NEUROBIOLOGY OF DEPRESSION
    Richard Shelton; Fiscal Year: 2003
    ..Develop further expertise in basic molecular biological methods; 2. Develop new projects oriented to future funding opportunities; and 3. Continue to mentor the next generation of investigators. ..